Skip to main content

Table 3 Biochemical assessments

From: Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study

  NR group
(N = 81)
IR/PR group
(N = 62)
P value
Total cholesterol (mmol/L) 4.43 ± 1.00 4.06 ± 0.96 0.029
Triglycerides (mmol/L) 2.11 ± 1.06 2.26 ± 1.51 0.498
HDL-C (mmol/L) 1.10 ± 0.26 1.06 ± 0.23 0.331
LDL-C (mmol/L) 2.57 ± 0.92 2.23 ± 0.71 0.017
Apo-A (mmol/L) 1.14 ± 0.18 1.11 ± 0.18 0.330
Apo-B (mmol/L) 0.90 ± 0.22 0.90 ± 0.22 0.902
Lp (a) 0.19 ± 0.11 0.19 ± 0.20 0.873
Fast glucose (mmol/L) 7.67 ± 2.82 7.38 ± 2.02 0.489
BUN (mmol/L) 5.94 ± 1.52 6.04 ± 1.82 0.718
Creatinine (mg/L) 84.84 ± 18.74 87.96 ± 30.66 0.454
Glycated haemoglobin (%) 7.92 ± 1.61 7.73 ± 1.39 0.451
hsCRP (mg/L) 5.33 ± 5.35 5.67 ± 7.02 0.745
esRAGE (ng/mL) 0.17 ± 0.09 0.24 ± 0.20 0.003
GA (%) 23.15 ± 5.24 19.64 ± 5.33 < 0.001
  1. NR, negative remodeling; IR/PR, intermediate or positive remodeling; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; Lp (a), lipoprotein (a); BUN, blood urea nitrogen; hsCRP, high sensitive C-reactive protein; esRAGE, endogenous secretory receptors for advanced glycation endproducts; GA, glycated albumin